Peri-aortic fat to assess cardiovascular aging using an AI-driven radiomic biomarker.
other
Where this comes from
- Record sourced from PubMed, PMID 42425447.
- Also identified by DOI 10.1093/eurheartj/ehag498.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Chronological age is central to cardiovascular disease (CVD) risk estimation but poorly reflects interindividual heterogeneity in cardiovascular aging. This study developed a peri-aortic adipose tissue (PAAT) radiomic cardiovascular age (CV-Age) biomarker from routine chest CT and tested whether the PAAT age gap (ΔAge = CV-Age - chronological age) stratifies major adverse cardiovascular events (MACE) and improves risk classification. Four chest CT cohorts with different protocols were utilized to train (n = 4451) and externally validate (n = 44 214) a CV-Age model. Associations between ΔAge decile groups (resilient ≤10th; accelerated ≥90th) and incident 5-point MACE (myocardial infarction, stroke, revascularization, heart failure, and death) were assessed using survival models. Clinical utility was evaluated by substituting CV-Age for chronological age in PREVENT to quantify risk reclassification. A 31-feature radiomic signature capturing PAAT volume, attenuation, and texture heterogeneity predicted age with good accuracy (training MAE 2.2 years; primary external validation MAE 2.7 years). In a separate higher-risk cohort, predictions showed a positive ΔAge (median +5.4 years), reflecting elevated baseline cardiovascular burden. ΔAge-stratified event-free survival differed across groups (log-rank P < .001); compared with normative agers, accelerated agers had higher MACE risk (HR 1.51, 95% CI 1.37-1.66), and resilient agers had lower risk (HR 0.70, 0.63-0.77). Substituting CV-Age into PREVENT improved risk reclassification (categorical NRI +0.03, P < .01, continuous NRI +0.04, P < .05). Radiomic profiling of PAAT on routine chest CT yields a scalable imaging biomarker of cardiovascular aging. CV-Age can help improve identification of higher-risk individuals missed by age-driven risk estimation, supporting its role as a risk-enrichment tool.